Insomnia - Causes, Consequences, and Evidence-Based Solutions

Roughly one in three adults reports insufficient sleep on most nights, and chronic insomnia disorder—defined by difficulty initiating or maintaining sleep at least three nights per week for at least three months, causing daytime impairment—affects an estimated 10–15% of adults globally. Despite its prevalence, insomnia is frequently undertreated, misunderstood, or managed with approaches that address short-term symptoms while perpetuating the underlying problem.

Primary vs. Secondary Insomnia

The historical distinction between “primary” insomnia (no identifiable cause) and “secondary” insomnia (caused by another condition) has been largely replaced in modern sleep medicine. Current thinking recognizes that most insomnia is comorbid—occurring alongside and interacting bidirectionally with other conditions—rather than simply caused by them.

For example, insomnia and depression are deeply intertwined: insomnia significantly increases depression risk, and depression reliably disturbs sleep. The comorbid framework demands treating both simultaneously.

Common conditions that co-occur with and perpetuate insomnia include:

Anxiety disorders — Racing thoughts, hyperarousal, and anticipatory worry are among the most powerful drivers of sleep-onset insomnia
Chronic pain — Disrupts sleep architecture, and sleep deprivation in turn lowers pain thresholds
Sleep-disordered breathing — Obstructive sleep apnea fragments sleep and causes non-restorative nights even when total duration seems adequate
Circadian rhythm disorders — Shifted sleep phase (common in adolescents and shift workers) produces insomnia at socially expected sleep times
Restless legs syndrome / periodic limb movement disorder — Motor symptoms that disturb sleep onset and maintenance
Fatigue syndromes — Conditions like fibromyalgia and CFS involve severe fatigue despite poor sleep quality

The Hyperarousal Model

Sleep is not simply the absence of waking—it is an actively generated state requiring suppression of arousal systems. The leading neurobiological model of chronic insomnia centers on hyperarousal: an elevation of physiological, cognitive, and cortical arousal that persists into the night and interferes with the arousal-suppression necessary for sleep onset.

Evidence for hyperarousal in insomnia includes elevated core body temperature (sleep requires a nocturnal drop in body temperature), increased whole-body metabolic rate, elevated cortisol in the evening (when it should be declining), and neuroimaging studies showing greater relative glucose metabolism in wake-promoting brain regions during NREM sleep in insomnia patients compared to normal sleepers.

This model has an important implication: the “racing mind” of insomnia is not psychological weakness—it reflects a measurable neurophysiological state, and it explains why simply “trying harder to sleep” or spending more time in bed typically makes chronic insomnia worse rather than better.

Cognitive Behavioral Therapy for Insomnia (CBT-I)

Every major sleep medicine guideline now positions CBT-I as the first-line treatment for chronic insomnia in adults—before pharmacotherapy. This reflects a substantial evidence base: meta-analyses consistently find that CBT-I produces durable improvements in sleep onset latency, wakefulness after sleep onset, and sleep efficiency, with effects maintained at 6- and 12-month follow-up. No sleeping medication demonstrates equivalent long-term outcomes.

CBT-I is a structured program typically delivered in 4–8 sessions that combines several components:

Sleep restriction therapy is the most powerful single component and the most counterintuitive. It involves temporarily limiting time in bed to match actual sleep time, creating mild sleep deprivation that consolidates and deepens sleep. As sleep efficiency improves, time in bed is gradually extended. This technique directly addresses the maladaptive behavior of spending excessive time in bed while awake—a behavior that conditions the brain to associate bed with wakefulness.

Stimulus control re-establishes the association between bed and sleep (rather than bed and lying awake, worrying, or using screens). Instructions include: use the bed only for sleep and sex; get out of bed if unable to sleep within 20 minutes; keep a consistent wake time regardless of how the night went.

Cognitive restructuring addresses dysfunctional beliefs about sleep (“I must get 8 hours or I’ll be useless tomorrow”; “I’m going to get sick if I don’t sleep”). These beliefs amplify arousal and create performance anxiety around sleep, which in turn impairs sleep.

Relaxation techniques including progressive muscle relaxation and mindfulness reduce physiological arousal at bedtime.

CBT-I is available via validated digital platforms (Sleepio, SHUTi, CBTI Coach) with evidence showing nearly equivalent outcomes to therapist-delivered treatment—a significant advance given therapist shortages.

Sleep Hygiene: What the Evidence Actually Shows

Sleep hygiene advice is ubiquitous but inconsistently supported. Here is what evidence does and does not back:

Supported by evidence:

Consistent wake time (stabilizes circadian rhythm; more important than consistent bedtime)
Avoiding caffeine within 6 hours of bedtime (caffeine has a 5–6 hour half-life)
Light exposure management: bright light in the morning advances sleep phase; blue-spectrum light in the evening delays melatonin onset
Cool bedroom temperature (18–20°C/64–68°F optimizes the nocturnal body temperature drop)
Avoiding alcohol: alcohol shortens sleep onset but severely fragments the second half of sleep and suppresses REM

Mixed or limited evidence:

Exercise: improves sleep quality but timing effects vary; vigorous exercise late in the evening may raise core temperature and delay sleep in some individuals
Heavy meals near bedtime: some evidence for worse sleep quality with late, large meals
“Wind-down” routines: plausible but few rigorous trials

Pharmacological Options

When medication is needed—for acute situational insomnia, as a bridge during CBT-I initiation, or for patients who don’t respond to behavioral treatment—several classes are available.

Z-Drugs (Non-Benzodiazepine GABA-A Modulators)

Zolpidem, zaleplon, and eszopiclone bind GABA-A receptors at the benzodiazepine site but with greater selectivity for receptor subtypes associated with sedation. They reduce sleep latency effectively and are well-tolerated in short-term use. Concerns include next-morning psychomotor impairment (particularly with extended-release zolpidem in women, who metabolize it more slowly), complex sleep behaviors (sleep-walking, sleep-eating, sleep-driving), and physical dependence with prolonged use. The FDA has required its strongest “black box” warning on Z-drugs for complex sleep behaviors.

Melatonin and Melatonin Receptor Agonists

Melatonin is most effective for circadian-based insomnia: delayed sleep phase syndrome, jet lag, and shift work. For primary insomnia without circadian disruption, the evidence for exogenous melatonin is modest. Dose matters: most commercial preparations (3–10 mg) substantially exceed physiological melatonin levels (peak ~0.1 mg). Low-dose melatonin (0.3–0.5 mg) may work as well or better by mimicking the physiological signal. Ramelteon, a melatonin receptor agonist, is FDA-approved for sleep-onset insomnia with no abuse potential.

Orexin Receptor Antagonists

Suvorexant and lemborexant represent a mechanistically novel class—rather than sedating the brain via GABA, they block the arousal-promoting orexin (hypocretin) system, essentially removing the neurochemical “brake” that keeps wakefulness active. This mechanism aligns directly with the hyperarousal model of insomnia. The orexin connection is also relevant to understanding narcolepsy, the condition caused by the loss of these same orexin neurons. Clinical trials show improvements in both sleep onset and sleep maintenance with a favorable next-morning profile compared to Z-drugs.

Sedating Antidepressants

Low-dose doxepin and trazodone are commonly prescribed for insomnia. Doxepin at doses of 3–6 mg (far below antidepressant doses) acts primarily as a histamine H1 antagonist and has an FDA indication for sleep maintenance insomnia. Its effects on sleep architecture are relatively clean.

What to Avoid

Benzodiazepines (temazepam, triazolam) are effective sedatives but suppress slow-wave sleep, carry significant dependence and withdrawal risk, and impair cognition in older adults. Diphenhydramine (common OTC sleep aids) develops rapid tolerance within 3–4 days, leaves next-day sedation, and is associated with increased dementia risk in older adults with long-term use.

The Health Consequences of Chronic Insomnia

Sleep is not merely restorative in a vague sense—it serves specific physiological functions that, when denied, produce measurable harm:

Cardiovascular: Chronic short sleep duration (<6 hours) is associated with a 20% increased risk of incident hypertension, 48% higher risk of coronary artery disease, and 15% increased stroke risk in meta-analyses
Metabolic: Sleep restriction promotes insulin resistance, increases appetite (via leptin/ghrelin dysregulation), and is a significant risk factor for type 2 diabetes
Immune: Sleep deprivation impairs NK cell activity, reduces vaccine antibody response, and increases susceptibility to respiratory viral infections
Cognitive: Chronic sleep restriction produces progressive cognitive impairment at deficits greater than subjects typically perceive—people underestimate their own impairment after multiple nights of inadequate sleep
Psychiatric: Insomnia is among the strongest modifiable risk factors for developing depression and anxiety disorders

Managing persistent fatigue—which insomnia reliably produces—often requires addressing sleep quality before resorting to stimulating agents. Wakefulness-promoting medications such as those in the modafinil category address fatigue symptoms in specific clinical contexts but do not treat the underlying sleep disorder.

Insomnia Across the Lifespan

Insomnia presentations differ meaningfully by age group, with important implications for evaluation and treatment selection.

Insomnia in adolescents is often driven by a biologically delayed sleep phase (circadian rhythm shift in adolescence) combined with early school start times and excessive screen exposure. Melatonin at low doses (0.5–1 mg) timed 1–2 hours before desired sleep onset can assist circadian adjustment, while CBT-I principles apply with age-appropriate modification.

Insomnia in adults frequently involves stress reactivity, work schedules, parenting demands, and caffeine use. The cognitive hyperarousal component — the racing mind — is often the primary target for CBT-I in this group.

Insomnia in older adults involves distinct physiology: natural shifts toward earlier sleep timing, reduced slow-wave sleep, increased nocturnal awakenings, and altered sleep homeostatic pressure. Comorbid conditions including pain, nocturia, restless legs syndrome, and cognitive decline contribute significantly. Pharmacological options require careful selection given age-related changes in drug metabolism and increased sensitivity to CNS effects.

Insomnia in menopause is common and often driven by vasomotor symptoms (hot flashes and night sweats) disrupting sleep continuity. Sleep disruption from vasomotor symptoms has a different treatment pathway than primary insomnia — addressing the hormonal trigger (through hormone therapy where appropriate) may be more effective than CBT-I or sedative-hypnotics in these cases.

The American Academy of Sleep Medicine publishes its clinical practice guidelines for behavioral and pharmacological treatment of insomnia at aasm.org. For a comprehensive evidence review, the NIH’s National Center on Sleep Disorders Research provides updated research summaries.